**ASX Release** **21st February 2014**

# Approval of Clinical Trial in Dogs for the Treatment of Canine Cancers

**PharmAust Limited** ("PharmAust") (ASX: PAA & PAAO) is pleased to announce that it has received approval from the Director General's Animal Care and Ethics Committee to commence the evaluation of PPL-1 in the treatment of canine cancers. The approval from the NSW Department of Primary Industries is for the Principal Investigator of the study, Dr Angela Frimberger (Veterinary Oncology Consultants), to evaluate PharmAust's lead product in the treatment of a variety of canine cancers.

PharmAust Ltd in conjunction with Vet Oncology Consultants Pty Ltd at the Animal Referral Hospital in Homebush, NSW, will now conduct a clinical trial to test the anticancer drug PPL-1 in a small number of pet dogs. The trial will test the safety and efficacy (Phase I/II) of PPL-1 for treating naturally occurring: superficial soft tissue sarcomas, chemo resistant lymphomas and metastatic melanomas. All pet dogs admitted to the trial will be treated with the drug by their owners at their homes. To determine the safest and most effective dose, the trial design will incorporate incremental increases in drug quantity to different groups of dogs. Groups of dogs will be administered higher doses only after safety and efficacy of the lower dose has been established. All dog owners, researchers, administrators and sponsors will know what drug and how much drug is being administered to the dogs (it is an open ended trial). Tumour size will be measured before and after treatment using callipers, CT (X-ray computed tomography) scan or radiographic imaging.

PharmAust's Executive Chairman, Dr Roger Aston said, "The US pet market is substantial with approximately 77.5 million pet dogs and 93.6 million cats* It is estimated that 60 percent of dogs over the age of 6 develop some form of cancer, according to Petplan Pet Insurance's claims. The US companion pet market sales (est. 2011) are in the region of US$14 billion whilst cancer therapies are estimated at $550 million with a price point of around $1,500 per treatment. As PPL-1 is already approved for veterinary use by PharmAust's partner, a top player in the Animal Health Industry, we believe that if successful in this trial, PPL-1 will be able to be approved quickly for the treatment of dog cancers following a further pivotal study"

*References:
2011-2012 National Pet Owners Survey Gabelli & Company, Inc. 2004. The US Veterinary health market.
http://www.vet-dc.com/25.html
American pet products manufacturers association, Inc. 2011-2012 National pet owner's survey

**For further details please contact:**

**Dr Roger Aston**
**Executive Chairman**
**PharmAust Limited**
**0402 762 204**